TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05375435
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
Study: NCT01692145
Drug: KCT-0809
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01692145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04827589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06329674
Drug: AJU-A51
Normalized name: AJUGA REPTANS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT06329674
Drug: AJU-A51 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT06329674
Drug: A51R2 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT06385847
Drug: LY01005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 3.6 mg intramuscular LY01005
Study: NCT05024422
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Pyridoxine (200 mg X 3 per day for a week)
Study: NCT00002122
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05455372
Drug: PPI quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
Study: NCT04731974
Drug: Melatonin 3 MG
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
Study: NCT04699123
Drug: NC318 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
Study: NCT00000959
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04853498
Drug: TQB3720
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an androgen receptor antagonists.
Study: NCT04871347
Drug: TWP-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04774822
Drug: Mydriatics Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye dilating agent
Study: NCT06364176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo through week 12
Study: NCT05195892
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Study: NCT04933799
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will match the study drug in dose, formulation, route and frequency.
Study: NCT04774952
Drug: RMC-5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-5552 for IV administration
Study: NCT05176782
Drug: HTK cardioplegia
Normalized name: cardioplegia solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
Study: NCT05176782
Drug: Cold Cadioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: as the will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
Study: NCT05072262
Drug: Nepafenac Ophthalmic
Normalized name: nepafenac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nepafenac (Nevanac) 3 mg/ml
Study: NCT04597099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Study: NCT04666922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; 0.9% saline for injection
Study: NCT05065190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00198302
Drug: Aurexis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05715736
Drug: APB-R3
Normalized name: APB 8 MG/ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.
Study: NCT05715736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.90% Normal Saline only
Study: NCT05342519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be assigned to received topical placebo cream to the lesion not being treated with the active study drug.
Study: NCT04830878
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic and intraoperative intravitreal injection of methotrexate
Study: NCT06280495
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours
Study: NCT06547385
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06547385
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06547385
Drug: Calcium Levofolinate Hydrateb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06478134
Drug: Trimix tear substitutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were instructed to instill 1 drop of TriMix tear substitute into each eye 3 times per day for 6 months.
Study: NCT04614298
Drug: KHK4827-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC administration
Study: NCT06483685
Drug: Radiopharmaceuticals drugs
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
Study: NCT04366518
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
Study: NCT05332106
Drug: Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climodien (Bayer plc.)
Study: NCT06284434
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive epinephrine (ratio of 1:100,000) mixed with the appropriate drug assigned to them based on their arm.
Study: NCT04599686
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.
Study: NCT05765747
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
Study: NCT05573100
Drug: CU06-1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
Study: NCT05247125
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg Melatonin pill will be given 1 hour before going to bed.
Study: NCT06108453
Drug: Methotrexate Sodium
Normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate oral administration alone
Study: NCT05946122
Drug: placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet resembles atorvastatin
Study: NCT06210061
Drug: Propofol-Fentanyl
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery. Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation.
Study: NCT06210061
Drug: Propofol-Fentanyl-Dexmedetomidine
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition patients will receive Dexmedetomidine (0.5ug.kg) loading dose infused over 10 mins followed by a constant infusion rate of (0.2ug/kg/hr). Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation.
Study: NCT06210061
Drug: Propofol-Fentanyl-Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition the anesthesia will be maintained with inhalational anesthesia of 50% oxygen , 50% air plus sevoflurane concentration adjusted to keep BIS between 40 \& 50 . Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation
Study: NCT05219929
Drug: Tetracycline 500 Mg
Normalized name: oxytetracycline 500 MG
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg three times daily
Study: NCT04128462
Drug: MNK-6105
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Ornithine Phenylacetate for IV infusion
Study: NCT04128462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for IV infusion
Study: NCT04128462
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
Study: NCT04205136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
Study: NCT05790525
Drug: Standard bismuth quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use the standard bismuth quadruple regimen recommended by the latest Chinese guidelines
Study: NCT04999605
Drug: AK112 medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor
Study: NCT04922996
Drug: Calcium Dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of calcium dobesilate in different tissues
Study: NCT05160311
Drug: Optimized Medical Treatment (OMT)
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized Medical Drug Treatment
Study: NCT04940182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo 2 times a day during 14 full days
Study: NCT05414552
Drug: ECP
Normalized name: Ecpirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
Study: NCT05041972
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
Study: NCT05780216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
Study: NCT04151472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet, three times a day
Study: NCT05663164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study: NCT05328024
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD1
Study: NCT04864717
Drug: Isotretinoin 40 mg po once daily x 6 months
Normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active intervention
Study: NCT05158023
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution for subcutaneous injection
Study: NCT05256693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycine placebo (powder) twice a day
Study: NCT05085561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT04102436
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study: NCT04469062
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04469062
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05275751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological intervention
Study: NCT04676711
Drug: GFH312
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
Study: NCT04676711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
Study: NCT04017390
Drug: Placebo Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply placebo foam alone
Study: NCT05004519
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dexmedetomidine or remifentanil during laparoscopic gastric bypass
Study: NCT05248646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo s.c. q 4 weeks
Study: NCT05434299
Drug: TFX05-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFX05-01 for intravenous
Study: NCT06315101
Drug: Chinese Herbal Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with Chinese herbal medicine (CHM). CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis. Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians. The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
Study: NCT05247697
Drug: Placebo oral tablet once daily at bedtime
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05046106
Drug: MLC1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
Study: NCT05033080
Drug: VX-121/TEZ/D-IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration.
Study: NCT05033080
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration.
Study: NCT05033080
Drug: Placebo (matched to ELX/TEZ/IVA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to ELX/TEZ/IVA for oral administration.
Study: NCT05033080
Drug: Placebo (matched to IVA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to IVA for oral administration.
Study: NCT04665362
Drug: Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib
Study: NCT05063968
Drug: XZP-6019 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet is administered orally once on Day 1 and Day 9, respectively
Study: NCT04772885
Drug: KT-474/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT-474 or matching placebo oral tablet(s)
Study: NCT05063968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet is administered orally once on Day 1 and Day 9, respectively
Study: NCT05063968
Drug: XZP-6019 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet is administered fasted orally once on Day 1
Study: NCT05063968
Drug: XZP-6019 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet is administered after a high-fat meal orally once on Day 9
Study: NCT05063968
Drug: XZP-6019 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet is administered orally once daily for 14 Days continuously
Study: NCT05063968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet is administered orally once daily for 14 Days continuously
Study: NCT05256810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by SC injection
Study: NCT05009199
Drug: [18F]MNI-444
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will undergo PET imaging using \[18F\]MNI-444.
Study: NCT05359055
Drug: SPH3127 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg once daily on Day 1 and Day 8
Study: NCT05359055
Drug: SPH3127 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg once daily on Day 1 and Day 12.
Study: NCT05865171
Drug: IXP
Normalized name: NovoSeven RT with MixPro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT04692805
Drug: cyanoacrylate glue
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS-guided injection of cyanoacrylate glue
Study: NCT04288206
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous normal saline placebo
Study: NCT05603832
Drug: F14
Normalized name: CATH,INTERM 14FR FEMALE CURE #F14
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625 mg intra-articular sustained-release celecoxib
Study: NCT05603832
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic
Study: NCT06009744
Drug: Low-dose vitamin C and zinc
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
Study: NCT06009744
Drug: High-dose vitamin C and zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
Study: NCT05953831
Drug: CDR132L
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
Study: NCT05953831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to CDR132L
Study: NCT05590143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
Study: NCT06333834
Drug: Traditional scorpion antivenom regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the classification proposed by the Mexican Clinical Practice Guideline to decide the dose of scorpion antivenom. Scorpion antivenom will be administered to all patients. Patients in this group will receive between one and three vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade I, two vials for patients classified as grade II, and three vials for patients classified as grade III)
Study: NCT06333834
Drug: Serial dose of scorpion antivenom regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the American classification to decide the dose of scorpion antivenom. Scorpion antivenom will be administered only in the presence of signs and/or systemic symptoms of intoxication, excluding signs and symptoms at the sting site. Patients in this group will receive between one and two vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade III and two vials for patients classified as grade IV)
Study: NCT05052710
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive oral doses once daily from Days 2-11.
Study: NCT05153785
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo